Acetylsalicylic acid represents one of the most transformative, extensively investigated, and ubiquitously prescribed pharmacological agents in the history of human medicine. From its ancient origins as a botanical extract derived from willow bark to its contemporary status as a cornerstone in cardiovascular prophylaxis, neurovascular risk reduction, and acute intervention, this prototypical compound bridges traditional therapeutics and modern molecular pharmacotherapy. Comprehending the multifaceted nature of acetylsalicylic acid requires exploring its biochemical mechanism, clinical versatility, evolutionary development, and the controversies defining its present therapeutic scope.
Acetylsalicylic Acid (ASA)
1. Concise Definition
Acetylsalicylic acid (ASA), commonly known by the trade name aspirin, is a synthetic nonsteroidal anti-inflammatory drug (NSAID) and platelet aggregation inhibitor characterized by the irreversible acetylation of cyclooxygenase enzymes. Chemically classified as 2-acetoxybenzoic acid, it exerts antipyretic, analgesic, anti-inflammatory, and antithrombotic actions across a broad continuum of clinical dose thresholds.
Unlike reversible NSAIDs, ASA establishes a permanent covalent modification within the active catalytic pockets of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2). Through this biochemical signature, ASA selectively impairs the synthesis of downstream eicosanoid mediators, most notably thromboxane A2 in circulating platelets and pro-inflammatory prostaglandins in peripheral somatic tissues. As a consequence, it functions both as an emergency intervention in acute thrombotic vascular events and as a therapeutic standard in long-term primary and secondary vascular protection.
2. Etymology & Linguistic Origin
The nomenclature of acetylsalicylic acid is rooted in historical botanical discoveries and classical chemical naming traditions. The term salicylic derives from the Latin noun salix (genitive salicis), signifying the willow tree, from whose bark and leaves natural salicylate derivatives were initially extracted. The prefix acetyl- denotes the addition of the acetyl acyl radical (CH3CO–), derived from the Latin acetum, meaning vinegar.
The trademark name Aspirin, coined in 1899 by the German chemical firm Bayer, was constructed systematically: the prefix A- represented the acetyl group; -spir- was drawn from Spiraea ulmaria (meadowsweet), a rich botanical source of salicylic acid; and the chemical suffix -in was conventionally appended to contemporary pharmaceuticals. Over the twentieth century, “aspirin” underwent widespread genericization in numerous jurisdictions, while “acetylsalicylic acid” and its abbreviation “ASA” remain standard in international chemical, clinical, and pharmacopeial documentation.
3. Pronunciation & Grammatical Form
Pronunciation: /əˌsiːtlˌsælɪˈsɪlɪk ˈæsɪd/ (uh-SEE-tuhl-sal-i-SIL-ik ASS-id).
Abbreviation: ASA.
Part of Speech: Compound noun (mass / non-count in typical clinical discourse; pluralized as acetylsalicylic acids when referring to multiple formulations, analogs, or preparations).
IUPAC Name: 2-acetyloxybenzoic acid.
Chemical Formula: C9H8O4.
Grammatical Variants: Salicylate (noun), acetylated (adjective/participle), salicylemia (noun, referring to serum concentration).
4. Detailed Conceptual Explanation
Acetylsalicylic acid occupies a unique place in clinical pharmacology due to its bifurcated, dose-dependent clinical behavior. At standard therapeutic concentrations, ASA acts through systemic enzymatic modulation rather than simple receptor antagonism. The molecular foundation of its pharmacological action resides in its non-selective, covalent inhibition of cyclooxygenase, also termed prostaglandin G/H synthase. COX enzymes catalyze the committed, rate-limiting step in the arachidonic acid cascade, converting membrane-liberated arachidonate into cyclic endoperoxides (prostaglandin G2 and prostaglandin H2).
By donating its acetyl group directly to a specific serine residue—Ser-529 in human COX-1 and Ser-516 in human COX-2—ASA places a steric obstruction across the narrow hydrophobic channel of the catalytic site. In COX-1, this covalent modification prevents arachidonic acid from entering the active pocket entirely, extinguishing the enzyme’s capacity to synthesize prostaglandin precursors. Because mature mammalian platelets are anucleate fragments incapable of de novo ribosomal protein translation, this covalent inhibition of platelet COX-1 is permanent for the remainder of the platelet’s circulating lifespan (typically 7 to 10 days). Consequently, production of thromboxane A2 (TXA2)—a potent stimulus of platelet aggregation, granule release, and vascular constriction—is suppressed.
Conversely, the acetylation of COX-2 by ASA does not completely abolish the enzyme’s oxygenase capacity; instead, it alters its stereospecificity. Acetylated COX-2 retains modified catalytic activity that redirects the oxidation of arachidonic acid away from pro-inflammatory prostaglandins and toward 15R-hydroxyeicosatetraenoic acid (15R-HETE). In adjacent vascular endothelial cells and leukocytes, 15R-HETE can be enzymatically converted into 15-epi-lipoxins, frequently termed “aspirin-triggered lipoxins” (ATLs). These endogenous specialized pro-resolving mediators stimulate anti-inflammatory and inflammation-resolving pathways, recruit non-phlogistic macrophages, and inhibit trans-endothelial neutrophil migration, contributing to ASA’s anti-inflammatory profile.
Pharmacokinetically, ASA demonstrates rapid absorption across the acidic milieu of the gastric mucosa and the upper proximal small intestine via passive non-ionic diffusion. Bioavailability ranges between 50% and 75% due to extensive first-pass de-acetylation in the gastrointestinal wall, liver parenchymal tissue, and circulating blood, mediated by nonspecific plasma and tissue esterases. The resulting primary metabolite, salicylic acid (salicylate), is itself biologically active, exerting reversible anti-inflammatory, antipyretic, and uricosuric actions. Salicylate undergoes saturable hepatic biotransformation through glycine conjugation (yielding salicyluric acid) and glucuronidation (forming salicyl acyl and phenolic glucuronides). Because these enzymatic clearance pathways follow Michaelis-Menten kinetics, clearance transitions from linear first-order elimination to non-linear zero-order elimination at moderate to toxic concentrations, causing half-life to expand from 20 minutes (for parent ASA) to 2–3 hours at low antiplatelet doses, and beyond 15–30 hours in cases of therapeutic saturation or acute overdose.
5. Historical Development
The therapeutic utility of salicylates extends thousands of years into antiquity. The Ebers Papyrus, dating from approximately 1534 BCE in ancient Egypt, documented the topical and systemic administration of willow leaf concoctions for inflammation, musculoskeletal pain, and localized ailments. Concurrently, Sumerian clay tablets and classical Greco-Roman texts by Hippocrates of Kos, Celsus, and Pliny the Elder recorded the therapeutic use of extracts derived from the bark and foliage of Salix species to ameliorate postpartum fever, rheumatism, and acute pain.
The formal scientific investigation of salicylates began in 1763, when Reverend Edward Stone presented a landmark paper to the Royal Society of London. Stone documented the successful administration of dried, powdered willow bark to fifty patients suffering from “ague” (intermittent malarial and non-malarial fevers), noting marked antipyretic and therapeutic success. By 1828, Johann Andreas Buchner, followed closely by French pharmacist Henri Leroux and Italian chemist Raffaele Piria, isolated and crystallized the bitter glucoside precursor, christening it salicin, which Piria subsequently converted into salicylic acid.
Although synthetic salicylic acid and sodium salicylate became widely accessible during the mid-nineteenth century, their clinical utility was constrained by profound gastric irritation, marked palatability issues, and acute gastrointestinal erosions. In 1853, French chemist Charles Frédéric Gerhardt synthesized acetylsalicylic acid by treating acetyl chloride with sodium salicylate, though he did not pursue its commercial or medical potential. In 1897, at the Bayer laboratories in Elberfeld, Germany, chemist Felix Hoffmann—working under the leadership of pharmaceutical research director Arthur Eichengrün and pharmacological inspector Heinrich Dreser—synthesized chemically stable, pure acetylsalicylic acid to develop an effective anti-arthritic remedy that would not cause the severe gastric distress his father experienced from raw sodium salicylate. Bayer registered the trademark Aspirin in 1899, launching its global clinical adoption.
The underlying molecular mechanism remained a mystery for over seven decades until British pharmacologist John R. Vane published his seminal 1971 work in Nature New Biology, demonstrating that aspirin and related NSAIDs selectively inhibit prostaglandin biosynthesis. This groundbreaking discovery earned Vane the 1982 Nobel Prize in Physiology or Medicine, shared alongside Sune Bergström and Bengt Samuelsson, transforming acetylsalicylic acid from an empirical remedy into a precisely understood biomolecular tool.
6. Theoretical & Pharmacological Foundations
The theoretical framework governing ASA sits within eicosanoid biochemistry, vascular biology, and hemostasis. The physiological arachidonic acid cascade is depicted below:
- Phospholipase A2 Activation: Membrane phospholipids undergo enzymatic cleavage by cytosolic Phospholipase A2 (PLA2) in response to physical, inflammatory, or thrombogenic stimuli, liberating free unesterified arachidonic acid.
- Enzymatic Bifurcation: Free arachidonate enters either the lipoxygenase (LOX) pathway, generating leukotrienes, or the cyclooxygenase (COX-1/COX-2) pathway, producing cyclic endoperoxides (PGG2 and PGH2).
- Downstream Cell-Specific Synthases: PGH2 serves as the obligate precursor substrate for terminal isomerases and synthases:
- Thromboxane Synthase (Platelets): Directs PGH2 toward Thromboxane A2 (TXA2), which prompts shape transformation, alpha/dense granule secretion, and conformational activation of the integrin alpha-IIb/beta-3 (GPIIb/IIIa) receptor complex.
- Prostacyclin Synthase (Endothelial Cells): Directs PGH2 toward Prostacyclin (PGI2), which stimulates endothelial adenylyl cyclase, increases cyclic AMP (cAMP), inhibits platelet aggregation, and induces localized vasodilation.
- Therapeutic Paradox and Selectivity: Low-dose ASA leverages a biological disparity between anucleate platelets and nucleated endothelial cells. Preserved trans-cellular endothelial synthesis of PGI2 can recover because endothelial cells rapidly synthesize new, unacetylated COX enzymes, whereas platelets cannot regenerate functional COX-1.
On an immunological level, high-dose ASA interrupts the activation cascade of Nuclear Factor Kappa B (NF-κB). By inhibiting the inhibitory kappa B kinase (IKK-beta) complex, ASA blocks the degradation of IκB, preventing NF-κB dimers from translocating to the nucleus. This downregulates the transcription of inducible pro-inflammatory genes, such as Interleukin-1 (IL-1), Tumor Necrosis Factor-alpha (TNF-α), Interleukin-6 (IL-6), and inducible Nitric Oxide Synthase (iNOS).
7. Key Components, Formulations & Dosages
Acetylsalicylic acid displays distinct clinical profiles depending on its formulation and target dosage window:
- Low-Dose / Antiplatelet Regimen (75 mg to 100 mg daily): Exclusively targets platelet COX-1. Used in primary and secondary vascular prophylaxis to prevent acute arterial thrombotic events, including myocardial infarction, transient ischemic attacks, and ischemic cerebrovascular accidents.
- Intermediate / Analgesic-Antipyretic Regimen (325 mg to 650 mg every 4–6 hours; max 4 g/day): Inhibits COX-1 and COX-2 throughout the peripheral and central nervous systems, lowering hypothalamic prostaglandin E2 (PGE2) to reset setpoint pyrexia and alleviate somatic nociception.
- High-Dose / Anti-Inflammatory Regimen (1000 mg to 4000 mg daily in divided doses): Historically utilized in acute rheumatic fever, active rheumatoid arthritis, systemic juvenile idiopathic arthritis, and Kawasaki disease to suppress chronic inflammation.
- Enteric-Coated Tablets: Engineered with a pH-sensitive polymer outer coat resistant to gastric hydrochloric acid, designed to dissolve exclusively in the neutral-to-alkaline duodenum to reduce direct mucosal irritation.
- Buffered Formulations: Compounded alongside antacid excipients (e.g., magnesium carbonate, aluminum hydroxide, calcium carbonate) to accelerate dissolution kinetics and attenuate mucosal acidity.
- Intravenous Formulations (e.g., Lysine Acetylsalicylate): Soluble salt esters developed for rapid parenteral delivery in emergency medical environments where oral administration is precluded.
8. Examples & Illustrative Clinical Cases
The following real-world clinical paradigms showcase the versatile therapeutic applications of ASA:
Case 1: Acute ST-Elevation Myocardial Infarction (STEMI). A 58-year-old individual presents to the emergency department with acute substernal chest pressure radiating to the left jaw, accompanied by diaphoresis. An electrocardiogram reveals ST-segment elevations in leads V1–V4. The emergency protocol demands the immediate administration of 162 mg to 325 mg of non-enteric-coated, chewable acetylsalicylic acid. Chewing promotes buccal mucosal absorption and rapid gastric entry, establishing antiplatelet action within 15 to 30 minutes. The immediate, near-total suppression of platelet thromboxane A2 stops coronary thrombus propagation over the ruptured atheromatous plaque, safeguarding the downstream myocardial microvasculature prior to emergent percutaneous coronary intervention (PCI).
Case 2: Prophylaxis for Preeclampsia in High-Risk Pregnancy. A 34-year-old primigravida with chronic essential hypertension and type 1 diabetes mellitus presents for prenatal consultation at 12 weeks of gestation. Recognizing her high baseline risk for preeclampsia, the obstetric team initiates low-dose ASA (81 to 150 mg daily) taken at bedtime from the 12th to 16th gestational week until delivery. The low-dose regimen preserves placental perfusion and curbs the systemic endothelial inflammation characteristic of early-onset preeclampsia by counterbalancing the abnormal systemic imbalance between placental thromboxane and prostacyclin synthesis.
Case 3: Acute Kawasaki Disease in Pediatrics. A 3-year-old child presents with a persistent six-day fever unresponsive to standard antipyretics, bilateral non-exudative conjunctival injection, a strawberry tongue, erythema of the oral mucosa, cervical lymphadenopathy, and induration of the hands and feet. Diagnosis of Kawasaki disease warrants admission for intravenous immunoglobulin (IVIG) and high-dose ASA (80 to 100 mg/kg/day divided into four doses). ASA combats profound systemic vasculitis in the acute phase, and is later down-titrated to a low antiplatelet dose (3 to 5 mg/kg/day) for 6 to 8 weeks to prevent life-threatening coronary artery aneurysms and secondary thrombosis.
9. Measurement & Assessment
Assessing ASA efficacy, therapeutic concentrations, and toxic overdoses requires distinct laboratory modalities:
In acute clinical overdose, serum salicylate concentration is determined through automated spectrophotometric assays based on Trinder’s reaction, in which salicylate reacts with ferric nitrate to yield a violet-colored complex. Measured levels are interpreted using the Done Nomogram to project severity and predict outcomes based on the estimated elapsed time since ingestion. Therapeutic salicylate serum levels for anti-inflammatory efficacy range from 15 to 30 mg/dL (150 to 300 mg/L), whereas toxic manifestations typically arise at concentrations exceeding 30 to 40 mg/dL, with concentrations over 100 mg/dL presenting life-threatening systemic toxicity.
When assessing antiplatelet pharmacodynamics or suspected aspirin non-responsiveness (aspirin resistance), static serum concentrations provide little clinical utility. Functional platelet assays are utilized instead:
- Light Transmission Aggregometry (LTA): The historical reference standard, evaluating light transmittance through platelet-rich plasma after adding arachidonic acid (0.5 mg/mL). Effective ASA therapy typically suppresses arachidonic acid-induced platelet aggregation below 20%.
- VerifyNow Aspirin Assay: A point-of-care turbidimetric optical detection system measuring aggregation across fibrinogen-coated beads in response to arachidonic acid, reporting results as Aspirin Reaction Units (ARU). Values < 550 ARU confirm therapeutic antiplatelet inhibition.
- Thromboelastography (TEG) with Platelet Mapping: Evaluates clot kinetics, viscoelastic strength, and platelet-mediated shear modulus in whole blood, quantifying the percentage of platelet inhibition driven by arachidonic acid.
- Urinary 11-Dehydro-Thromboxane B2: A non-invasive enzyme-linked immunosorbent assay (ELISA) measuring the major stable urinary breakdown product of TXA2, reflecting systemic in vivo platelet activation.
10. Applications & Practical Significance
The clinical scope of acetylsalicylic acid spans multiple operational fields within internal medicine:
Cardiovascular and Neurovascular Therapeutics: In acute coronary syndromes (unstable angina, NSTEMI, STEMI) and acute non-cardioembolic ischemic strokes, ASA acts as an indispensable first-line intervention. In secondary prevention, lifelong low-dose ASA therapy reduces long-term vascular death, recurrent myocardial infarction, and stroke by roughly 20% to 25% across broad patient cohorts.
Structural and Interventional Cardiology: Following coronary stent implantation, ASA represents an obligatory component of Dual Antiplatelet Therapy (DAPT) alongside a P2Y12 adenosine diphosphate receptor antagonist (e.g., clopidogrel, ticagrelor, or prasugrel) to prevent acute, subacute, and late stent thrombosis.
Oncological Prophylaxis: Substantial epidemiological and randomized controlled clinical evidence supports the role of sustained, long-term ASA administration in lowering the incidence and mortality of adenomatous colorectal polyps and sporadic colorectal carcinoma (CRC), along with secondary risk reduction in patients carrying pathogenic DNA mismatch repair mutations (Lynch syndrome). The proposed mechanisms involve chronic inhibition of COX-2-dependent Wnt/beta-catenin signaling, downregulation of epidermal growth factor receptor (EGFR) activation, and the suppression of platelet-derived growth factors that facilitate metastatic seeding.
11. Research & Empirical Evidence
The pharmacological utility of acetylsalicylic acid is supported by an extensive clinical trial record spanning over four decades:
The ISIS-2 Collaborative Trial (1988): The Second International Study of Infarct Survival (ISIS-2) evaluated 17,187 patients presenting with acute myocardial infarction. The trial demonstrated that low-dose ASA (162 mg daily for one month) produced a 23% relative risk reduction in 5-week vascular mortality, an efficacy comparable to intravenous streptokinase alone. When combined, ASA and streptokinase reduced 5-week vascular mortality by 42%, firmly establishing emergent aspirin therapy as a global standard of care.
The Primary Prevention Conundrum: Landmark trials such as ASPREE (Aspirin in Reducing Events in the Elderly, 2018), ARRIVE (Aspirin to Reduce Risk of Initial Vascular Events, 2018), and ASCEND (A Study of Cardiovascular Events in Diabetes, 2018) re-evaluated the balance of risks and benefits for primary vascular prophylaxis in modern, statin-treated populations without pre-existing occlusive vascular disease. The findings demonstrated that while low-dose ASA produces modest reductions in primary ischemic events, these benefits are offset by marked increases in major gastrointestinal hemorrhage and intracranial bleeding. Consequently, current clinical practice guidelines from the American College of Cardiology (ACC), American Heart Association (AHA), and European Society of Cardiology (ESC) advise against the routine initiation of primary prevention ASA in low-risk individuals and adults over the age of 70.
The CAPP2 Trial: The Colorectal Adenoma/Carcinoma Prevention Programme 2 (CAPP2) demonstrated that in patients with Lynch syndrome, continuous daily administration of 600 mg of ASA for a minimum of two years reduced colorectal cancer incidence by nearly 50% over an extended follow-up period of ten years, establishing a critical role for ASA in precision oncological chemoprevention.
12. Cultural & Cross-Cultural Considerations
Cultural interpretations, international prescribing norms, and regulatory practices surrounding acetylsalicylic acid reveal distinct regional variations. In high-income nations, ASA is readily accessible over-the-counter as an inexpensive commodity, frequently consumed informally for minor headaches, common colds, and generalized malaise.
Conversely, in many low- and middle-income countries (LMICs), accessibility to verified, low-cost secondary preventive therapies remains a public health obstacle. Despite ASA’s inclusion on the World Health Organization (WHO) Model List of Essential Medicines, real-world availability, patient adherence, and public understanding of low-dose preventative antiplatelet therapy for coronary and cerebrovascular disease diverge widely. Furthermore, divergent regulatory models emerge in the marketing of combinations: some countries permit uncontrolled over-the-counter sales of multi-ingredient analgesic formulations combining ASA with caffeine, acetaminophen, or codeine, heightening the risk of medication-overuse headaches and hidden chronic toxicity.
13. Criticisms, Debates & Adverse Effects
Despite its profound utility, acetylsalicylic acid possesses considerable liabilities that demand active clinical vigilance:
Gastrointestinal Injury: ASA’s dual mechanism—direct physicochemical topical damage to the gastric mucosal barrier and systemic depletion of cytoprotective prostaglandin E2 and prostacyclin via mucosal COX-1 inhibition—leads to superficial erosions, peptic ulceration, and upper gastrointestinal hemorrhage. This liability is mitigated clinically by concurrent prescription of proton pump inhibitors (PPIs) in high-risk patients.
Reye’s Syndrome: The administration of ASA in pediatric populations and adolescents suffering from acute viral illnesses (notably influenza A, influenza B, or varicella zoster) is linked to Reye’s syndrome. This devastating mitochondrial hepatocerebral disorder features acute non-inflammatory microvesicular hepatic steatosis, severe hyperammonemia, and rapidly progressive cerebral edema. Consequently, ASA is strictly contraindicated in children and adolescents under 16 to 19 years of age, except in targeted conditions such as Kawasaki disease.
Aspirin-Exacerbated Respiratory Disease (AERD): Also known as Samter’s triad, this chronic non-allergic condition is characterized by adult-onset asthma, recurrent hyperplastic eosinophilic rhinosinusitis with nasal polyposis, and acute respiratory reactions upon ingesting ASA or other non-selective COX inhibitors. Pharmacological blockage of the COX pathway shunts arachidonic acid toward 5-lipoxygenase (5-LOX), causing unrestrained, excessive production of bronchoconstrictive cysteinyl leukotrienes (LTC4, LTD4, LTE4).
Salicylate Intoxication (Salicylism): Acute or chronic ASA overdose triggers complex systemic metabolic disturbances:
- Early Respiratory Alkalosis: Salicylate directly stimulates the medullary respiratory center, provoking tachypnea, hyperventilation, and carbon dioxide washout.
- Secondary Anion-Gap Metabolic Acidosis: Uncoupling of oxidative phosphorylation in the mitochondrial electron transport chain forces reliance on anaerobic glycolysis, driving accumulation of lactic acid, pyruvic acid, and ketone bodies.
- Clinical Presentation: Tinnitus, sensorineural hearing loss, vertigo, nausea, vomiting, agitation, hyperpyrexia, delirium, non-cardiogenic pulmonary edema, and metabolic collapse.
- Treatment Interventions: Aggressive gastric decontamination, continuous intravenous sodium bicarbonate infusions to alkalinize urine (pH > 7.5) and trap salicylate ions to expedite renal clearance, and emergent hemodialysis in severe presentations.
14. Related Terms & Distinctions
Understanding acetylsalicylic acid requires distinguishing it from related analgesics, anti-inflammatory compounds, and antithrombotic medications:
- Salicylic Acid: The unacetylated parent compound. It cannot donate an acetyl moiety, and therefore does not irreversibly inactivate COX-1; it is too damaging to the gastric mucosa for standard oral use and is predominantly employed as a topical keratolytic agent.
- Acetaminophen (Paracetamol): A centrally active aniline derivative with analgesic and antipyretic properties, but minimal peripheral anti-inflammatory or antiplatelet activity. Acetaminophen does not induce significant gastric ulceration, nor does it cause Reye’s syndrome, but can induce acute centrilobular hepatic necrosis in high doses.
- Ibuprofen & Traditional NSAIDs: Non-steroidal anti-inflammatory agents that bind reversibly through competitive antagonism at the COX-1 and COX-2 active sites. Their antiplatelet actions correlate directly with systemic clearance, dissipating as the drug is metabolized, unlike the permanent suppression produced by ASA.
- Selective COX-2 Inhibitors (Celecoxib): Synthetic compounds tailored to spare constitutive mucosal COX-1 while inhibiting inducible pro-inflammatory COX-2. They feature reduced gastrointestinal toxicity, but lack the irreversible antiplatelet properties of ASA and may heighten cardiovascular thrombotic risk when unopposed by COX-1 inhibition.
- Clopidogrel & P2Y12 Inhibitors: Antiplatelet agents that target the P2Y12 platelet adenosine diphosphate (ADP) receptor, arresting downstream Gi signaling and ADP-mediated activation of the GPIIb/IIIa receptor complex. They frequently serve as adjunctive partners with or alternatives to ASA.
15. Summary & Key Takeaways
Acetylsalicylic acid remains a foundational achievement in pharmacological chemistry, medicinal synthesis, and targeted therapeutics. As an irreversible modifier of cyclooxygenase enzymes, it exhibits a versatile, dose-dependent clinical pharmacology. At low doses, it suppresses platelet thromboxane A2 to offer cost-effective, lifelong antiplatelet vascular protection. At elevated concentrations, it inhibits systemic prostaglandin production, functioning as an effective analgesic, antipyretic, and anti-inflammatory therapy.
While its secondary cardiovascular benefits are definitively established, clinical practice has grown increasingly cautious regarding its role in broad-spectrum primary cardiovascular prevention due to the ever-present danger of gastrointestinal and intracranial hemorrhage. Contraindications in febrile pediatric patients (due to Reye’s syndrome) and those with respiratory hypersensitivity (AERD) necessitate thoughtful clinical management. Current investigations continue to explore ASA’s promising potential as a long-term chemopreventive agent against gastrointestinal malignancies, reinforcing its position as one of the most enduring, clinically valuable compounds in modern medicine.
References
- Antithrombotic Trialists’ (ATT) Collaboration. (2009). Collaborative meta-analysis of individual participant data from randomised trials of aspirin for primary and secondary prevention of vascular disease. The Lancet, 373(9678), 1849–1860. https://doi.org/10.1016/S0140-6736(09)60503-1
- Burn, J., Sheth, H., Elliott, F., Reed, L., Macrae, F., Mecklin, J. P., Möslein, G., Sampson, J. R., Evans, D. G., & CAPP2 Investigators. (2020). Cancer prevention with aspirin in gene carriers of Lynch syndrome: 10-year follow-up and registry study of the CAPP2 randomised controlled trial. The Lancet, 396(10250), 354–364. https://doi.org/10.1016/S0140-6736(20)30366-4
- ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. (1988). Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. The Lancet, 332(8607), 349–360. https://doi.org/10.1016/S0140-6736(88)92833-4
- McNeil, J. J., Wolfe, R., Woods, R. L., Tonkin, A. M., Donnan, G. A., Nelson, M. R., Reid, C. M., Lockery, J. E., Kirpach, B., & ASPREE Investigator Group. (2018). Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. The New England Journal of Medicine, 379(16), 1509–1518. https://doi.org/10.1056/NEJMoa1805819
- Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biology, 231(25), 232–235. https://doi.org/10.1038/newbio231232a0